Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q4 2020 Earnings Presentation

35 slides from Walgreens Boots Alliance's earnings presentation, Oct 15, 2020

  1. Slide 1: Fourth Quarter and Fiscal 2020 Results

    Fourth Quarter and Fiscal 2020 Results October 15, 2020

  2. Slide 2: Safe harbor and non-GAAP

    Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not historical including, without limitation, estimates of and goals for future financial, tax and operating performance and results and our fiscal y

  3. Slide 3: Overview

    Overview • 4Q20 results at high end of our expectations • Full year pulled down by 2H COVID impact • Robust financials with strong and reliable cash flow • Trends showing signs of gradual recovery for year ahead • Demonstrable benefits from accelerating digitalization program − customer experience b

  4. Slide 4: 4Q and FY20 financial highlights

    4Q and FY20 financial highlights • FY20 adjusted EPS $4.74, at high end of guidance range − -20.6% below last year in constant currency; estimated COVID-19 impact ~-$1.06 • 4Q adjusted EPS $1.02 versus $1.43 in prior year, -27.9% in constant currency − estimated COVID-19 impact ~-$0.46 • Transformat

  5. Slide 5: Fiscal year financial highlights

    Fiscal year financial highlights Reported currency Constant currency FY20 Δ vs. FY19 Δ vs. FY19 $ in millions (except EPS and % change) Sales $139,537 + 2.0% + 2.5% Operating income: GAAP $1,312 - 73.7% Adjusted $5,211 - 24.9% - 24.8% Net earnings: GAAP $456 - 88.5% Adjusted $4,175 - 24.5% - 24.3% E

  6. Slide 6: 4Q financial highlights

    4Q financial highlights Reported currency Constant currency 4Q20 Δ vs. 4Q19 Δ vs. 4Q19 $ in millions (except EPS and % change) Sales $34,746 + 2.3% + 2.3% Operating income: GAAP $650 - 26.0% Adjusted $1,126 - 27.7% - 27.4% Net earnings: GAAP $373 - 44.9% Adjusted $887 - 30.9% - 30.6% EPS: GAAP $0.43

  7. Slide 7: Retail Pharmacy USA – financials

    Retail Pharmacy USA – financials $ in millions (except %) 4Q20 Δ vs. 4Q19 FY20 Δ vs. FY19 Sales $26,967 + 3.6% $107,701 + 3.0% Adj. gross profit $5,455 - 4.5% $22,432 - 5.4% Adj. SG&A % of sales 17.0% - 0.6%p 17.0% - 0.6%p Adj. operating margin 3.3% - 1.1%p 3.8% - 1.2%p Adj. operating income $884 -

  8. Slide 8: Retail Pharmacy USA – pharmacy

    Retail Pharmacy USA – pharmacy Comparable 2Q 3Q 4Q Year Pharmacy sales + 3.7% + 3.5% + 3.2% + 3.2% Prescriptions + 4.9% + 0.4% + 3.6% + 2.9% • 4Q Rx comp scripts up +3.6%, sequential script growth improvement of +320bps − remains below 2Q pre-pandemic level of +4.9% − improved 4Q trends in new to th

  9. Slide 9: Retail Pharmacy USA – retail

    Retail Pharmacy USA – retail Comparable 2Q 3Q 4Q Year Comp sales + 0.6% + 1.9% + 4.7% + 1.6% Store gross margin + 95bps - 80bps - 10bps + 5bps • 4Q retail comp sales up +4.7%, sequential quarterly improvement of +280bps − excluding tobacco and e-cigarettes retail comp sales were up +6.5% − first mov

  10. Slide 10: Retail Pharmacy International – financials

    Retail Pharmacy International – financials Constant currency Constant currency $ in millions (except %) 4Q20 Δ vs. 4Q19 FY20 Δ vs. FY19 Sales $2,300 - 15.4% $10,004 - 11.1% Adj. operating margin - 0.1% - 7.2%p 1.3% - 5.3%p Adj. operating income - $3 - 100.7% $130 - 83.6% Boots UK comp. pharmacy sale

  11. Slide 11: Boots UK – financials

    Boots UK – financials Comparable 2Q 3Q 4Q Year Pharmacy sales + 1.8% - 1.0% + 0.4% + 0.5% Retail sales - 4.6% - 48.0% - 29.2% - 19.1% Retail adj. GM% - 65bps - 440bps - 710bps - 310bps • Pharmacy comps impacted by lower demand for scripts & Rx services notably in city centers, offset by NHS funding

  12. Slide 12: Retail Pharmacy International – initiatives

    Retail Pharmacy International – initiatives Boots UK turnaround key priority for FY21 • Swift actions including targeted marketing activity leading to improved performance • Boots.com continues to be a top UK online destination for consumers − strong growth in Boots.com, sales up +155% in 4Q vs. +78

  13. Slide 13: Pharmaceutical Wholesale – financials

    Pharmaceutical Wholesale – financials Constant currency Constant currency $ in millions (except %) 4Q20 Δ vs. 4Q19 FY20 Δ vs. FY19 Sales $5,987 + 4.3% $23,958 + 6.5% Adj. operating margin 2.3% + 0.1%p 2.3% - 0.1%p Adj. operating income $245 + 8.3% $980 + 5.8% • Continued good sales growth led by eme

  14. Slide 14: Cash flow

    Cash flow $ in millions FY20 B+/(w-) vs. FY19 Operating cash flow $ 5,484 - $109 Capital expenditure $ 1,374 + $328 Free cash flow $ 4,111 + $219 • Strong cash flow generation driven by working capital optimization • Free cash flow +$0.2bn vs. prior year, despite estimated COVID-19 AOI impacts ~-$1.

  15. Slide 15: Transformational Cost Management Program

    Transformational Cost Management Program On target to deliver in excess of $2.0 billion in annual cost savings by FY22 • Retail Pharmacy USA − store operating model transformation is underway − closed 215 locations, returns ahead of expectations & now planning ~250 closures • Boots UK − closed 138 o

  16. Slide 16: Fiscal year 2021 guidance assumptions

    Fiscal year 2021 guidance assumptions • Adj. effective tax rate ~15.5% • Share repurchase (excluding anti-dilutive) None • Currency favorable impact (GBP 1.29 | EUR 1.15) ~$0.01 • Investments in digital, development and omni-channel ~3% Adj. EPS • Transformational Cost Management Program >$2.0 bn by

  17. Slide 17: Fiscal year 2021 guidance

    Fiscal year 2021 guidance Constant currency adjusted EPS growth: low-single digit Phasing assumptions: • 1H21 adj. EPS: -17% to -23% − 1H21 expected to be negatively impacted by COVID-19 − includes lapping 1Q20 tax benefits; ~6 percentage points impact in 1Q21 • 2H21 adj. EPS: +30% to +40% − lapping

  18. Slide 18: Financial summary

    Financial summary • 4Q results were at the high end of guidance • Strong financial position with FY20 free cash flow $4.1bn, growth of +5.6% vs. prior year • Introducing FY21 adj. EPS guidance of low single digit growth at constant currency − 1H pressured by continued COVID-19 impacts − 2H expect to

  19. Slide 19: Retail Pharmacy USA – initiatives

    Retail Pharmacy USA – initiatives Delivering essential services while accelerating our digital transformation • Relaunched Prescription Savings Club – enrollment up over +400% since relaunch • Providing personalized guidance on health & Rx coverage options through FindRx Coverage Advisor • Continue

  20. Slide 20: Redesigned Mobile App Experience

    1. Redesigned Mobile App Experience as Gateway to Health & Wellbeing 2. Loyalty Rewards Reimagined © 2020 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 24 20

  21. Slide 21: Launching November 2020

    Launching November 2020 © 2020 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 24 21

  22. Slide 22: New and streamlined features will markedly improve the customer experience

    New and streamlined features will markedly improve the customer experience New App / Branding Currency Walgreens Cash rewards Digital wallet, new healthcare services, personalized Digital-First Engagement relationship management Community Focus Donate for community causes Daily Recommendations, Tuto

  23. Slide 23: Refer to safe harbor and non-GAAP on page 2 and endnotes on page 24

    © 2020 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 24 23

  24. Slide 24: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures. • The company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  25. Slide 25: Appendix

    Appendix The following information provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting princip

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q19 Twelve months ended August 31, Change vs. FY19 2020 2019 Amount Percent 2020 2019 Amount Percent

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS PER SHARE Three months ended August 31, Change vs. 4Q19 Twelve months ended August 31, Change vs. FY19 2020 2019 Amount Percent 2020 2019 Amount Per

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2020 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale¹ Eliminations Alliance, Inc.

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2019 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale¹ Eliminations Alliance, Inc.

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2020 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale¹ Eliminations Alliance, Inc.

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2019 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale¹ Eliminations Alliance, Inc.

  32. Slide 32: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures EQUITY EARNINGS IN AMERISOURCEBERGEN Three months ended August 31, Twelve months ended August 31, 2020 2019 2020 2019 Equity earnings in AmerisourceBergen (GAAP) $ 57 $ 59 $ 341 $ 164 Acquisition-related amortization 29 30 120 125 Asset Impairment — (1)

  33. Slide 33: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended August 31, 2020 Three months ended August 31, 2019 Earnings before Earnings before income tax provision Inco

  34. Slide 34: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended August 31, Twelve months ended August 31, 2020 2019 2020 2019 Net cash provided by operating activities (GAAP) $ 2,086 $

  35. Slide 35: Currency sensitivity

    Currency sensitivity Exchange Rates/Impact (constant currency based on FY20) FY20 FY21 GBP/USD 1.27 1.29 EUR/USD 1.11 1.15 TRY/USD 0.16 0.14 Fx Sales Impact vs. FY20 ~$275m / ~0.2% Fx Adj. Operating Income Impact vs. FY20 ~$0m / ~0.0% Fx Adj. EPS Impact vs. FY20 ~$0.01 / ~0.1% • Every 1% move in GBP

Walgreens Boots Alliance — Q4 2020 Earnings Presentation on 6ix